Novartis reported this Wednesday that it will invest 50 million dollars in clinical research in Mexico in the next three years.
Fernando Cruz, president of Novartis Mexico, and the Undersecretary of Economy, Héctor Guerrero, announced the investment in a press conference at the headquarters of the Ministry of Economy.
Cruz highlighted that the pharmaceutical company plans to develop a regional clinical research center in Mexico.
The investment is included as part of a memorandum of understanding signed between Novartis and the Ministry of Economy, in which the company also undertakes to promote small and medium-sized companies (SMEs) and promote the acceleration of digitization, among other points.
Cruz said that Mexico has the potential to attract more global investment in this industry and that Novartis operates in 155 countries, of which 15 are considered “strategic markets,” including Mexico.
In 2021, Novartis generated some 12,000 direct and indirect jobs in Mexico and contributed $ 400 million to the country’s Gross Domestic Product (GDP).
In turn, Guerrero said that Novartis’ investment will allow the development of “well-paid” jobs and boost the country’s economic development.
Novartis’ research program is run by the Novartis Institutes for Biomedical Research (NIBR), which is the company’s early research and development innovation engine.
NIBR is responsible for the discovery of new drugs for diseases with unmet medical need.
The company focuses its work on areas where it believes it can have the greatest impact for patients.
This requires the hiring and retention of highly talented employees, a focus on the fundamental mechanisms of disease that are relevant to different areas of the disease, continuous improvement in technologies for drug discovery and potential therapies, close partnerships with clinical colleagues. and the establishment of external strategic alliances.
Cruz highlighted that, on average, for every dollar invested in clinical research, an impact of between $ 1.8 and $ 3 is generated in the economy.
roberto.morales@eleconomista.com.mx
kg